SÍNDROME CARDIOVASCULAR–RIÑÓN–METABOLISMO (CKM): AVANCES EN LA PREVENCIÓN Y EL MANEJO INTEGRAL BASADOS EN EVIDENCIA CIENTÍFICA
Open Access
- 16 September 2026
- journal article
- Published by InvestiGO in VitalyScience Revista Científica Multidisciplinaria
- Vol. 4 (11) , 14-30
Abstract
The cardiovascular-kidney-metabolic (CKM) syndrome is a comprehensive clinical framework proposed in 2023 by the American Heart Association. This approach describes how the pathophysiological interconnections between adipose tissue accumulation or dysfunction, metabolic risk factors, chronic kidney damage, and cardiac conditions interact. The purpose of this systematic review was to summarize the scientific literature published from 2021 to 2026 on advances in the comprehensive management and prevention of CKM. To achieve this, we conducted an exhaustive search of databases such as PubMed/MEDLINE, Embase, the Cochrane Library, Scopus, and Web of Science, following the criteria of the PRISMA 2020 guidelines. We evaluated clinical guidelines, expert consensus statements, randomized clinical trials, meta-analyses, and key observational studies. Classifying this condition into five stages (0 through 4) helps stratify risk and guides clinical intervention from the earliest stages. In turn, the PREVENT assessment tools facilitate the calculation of 10- and 30-year cardiovascular events by integrating renal and metabolic markers. From a therapeutic perspective, treatment options with cardiorenal benefits particularly SGLT2 inhibitors and GLP-1 receptor agonists have been shown to significantly reduce serious cardiovascular outcomes, the progression of kidney failure, and overall mortality. In the context of Latin America and Ecuador, the high prevalence of obesity, type 2 diabetes, and hypertension, coupled with inequities in access to healthcare, further complicates the burden of disease. In conclusion, implementing a multidisciplinary strategy focused on healthy habits, close monitoring of key indicators, and early prescription of drugs with multiorgan protection is the most effective approach to slowing the progression of CKM and even reversing its stages.Keywords
This publication has 20 references indexed in Scilit:
- Epidemiology of cardiovascular–kidney–metabolic syndromeNature Reviews Nephrology, 2026
- Readiness to deliver integrated cardiovascular, kidney and metabolic care in primary healthcare: phase II of HEARTS 2.0 in 26 countries in the AmericasBMJ Global Health, 2026
- Associations between cardiovascular-kidney-metabolic syndrome staging and risks of all-cause and cardiovascular mortality: a systematic review and meta-analysisAmerican Journal of Preventive Cardiology, 2026
- Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020JAMA, 2024
- Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020JAMA Cardiology, 2023
- Empagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2023
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection FractionNew England Journal of Medicine, 2022
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsBMJ, 2021
- Understanding the rise of cardiometabolic diseases in low- and middle-income countriesNature Medicine, 2019
- Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart AssociationCirculation, 2019